ResultsIQ › Latest results › Molbio Diagnostics Limited
Molbio Diagnostics Limited Q2 FY27 results deck summary
NSE: MOLBIO · BSE: 544866
Results deck of 5 Nov 2026, summarised by AI from the filing.
Q2 FY27 total income fell to ₹264.8 cr on rate-contract negotiations, while management reiterated 25% topline growth guidance for FY27.
Key takeaways
- Q2 result Q2 FY27 total income was ₹264.8 cr (Q2 FY26: ₹581.4 cr), EBITDA ₹49.7 cr at 18.8% and PAT ₹7.7 cr at 2.9%.
- FY27 guidance Management reiterated guidance of 25% topline growth in FY27 over FY26.
- Q2 softness Q2 FY27 was softer as the company was in the midst of rate-contract negotiations, so the quarter does not reflect a full three months of sales.
- Exports Outside India rose to 21% of Q2 FY27 revenue from 7% in Q2 FY26 as the company expands its global footprint.
- Margin fall EBITDA margin fell to 18.8% in Q2 FY27 from 29.0% in Q2 FY26.
Molbio Diagnostics Limited H1 FY27 results
As filed: Revenue ₹648 cr, EBITDA ₹150 cr, PAT ₹88.0 cr, EBITDA margin 23.2%.
Not scored. No result for the same half-year last year.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%. Not scored. No result for the same quarter last year. Share price after the results: +29.5% in 30 days (Nifty 500: −5.5%).
Past price moves after results do not indicate future moves. Not a recommendation.
Molbio Diagnostics Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.